Compositions and methods for detecting viruses in a sample

ABSTRACT

The present disclosure provides a composition comprising a panel of probes for detecting one or more viruses in a sample. The panel of probes may be used to detect viruses in a biological sample obtained from a subject.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application 62/289,011 filed Jan. 27, 2016, which is hereby incorporated by reference in its entirety.

GOVERNMENTAL RIGHTS

This invention was made with government support under R01 AI097213 awarded by the National Institutes of Health. The government has certain rights in the invention.

FIELD OF THE INVENTION

The present disclosure provides a composition comprising a panel of probes for detecting one or more viruses in a sample. The panel of probes may be used to detect viruses in a biological sample obtained from a subject.

BACKGROUND OF THE INVENTION

High-throughput, massively parallel nucleotide sequence analysis has made in-depth studies of the human microbiome feasible. Thus far, most microbiome studies have focused on bacteria, although some include fungi. Viruses are particularly understudied, in part due to the challenges of assessing their presence in clinical samples. Viruses as a group have highly variable genomes, with no gene shared among all viruses that can be surveyed by an amplicon-based sequencing strategy. Therefore, studies of viruses based on nucleotide sequencing require a metagenomic approach. Metagenomic shotgun sequencing (MSS) is a relatively unbiased, culture-independent method in which nucleic acid extracted from a sample is sequenced. Sequence reads are classified based on similarity to reference genomes. This approach allows comprehensive study of the viral component of the microbiome (the virome) and has led to the discovery of novel viruses and the characterization of viruses present in healthy and sick people. When adequate numbers of sequence reads are generated, viruses can be characterized with regard to taxonomy and the presence of genes associated with virulence and resistance to antiviral drugs.

A limitation of MSS as employed to date for virus detection is that the amount and proportion of viral nucleic acid in samples from humans may be very low, and in these cases, few viral sequences are generated. Additionally, it has been shown that viruses known to be present based on molecular assays are undetectable using MSS. These difficulties may reflect the small genome size of some viruses and/or low levels of virus in the sample. This can be a particular problem for studies of the virome of healthy, asymptomatic individuals, in whom virus levels may be low. Thus, there is a need for a method of enriching viral sequences in a metagenomic sample prior to sequencing.

SUMMARY OF THE INVENTION

In an aspect, the disclosure provides a method to detect one or more viruses in a sample. The method comprises: a) contacting a sample with a panel comprising probes capable of specifically hybridizing to greater than 10,000 viral nucleic acid sequences; b) isolating the probes that specifically hybridize to viral nucleic acid sequences within the sample; c) sequencing the viral nucleic acid sequences isolated; and d) comparing the sequences from (c) with a database comprising reference viral nucleic acid sequences to determine the identity of the viral nucleic acid in the sample.

In another aspect, the disclosure provides a kit for detecting viral nucleic acid. The kit comprises probes capable of specifically hybridizing to greater than 10,000 viral nucleic acid sequences.

In still another aspect, the disclosure provides a cohort of viral nucleic acid sequences. The cohort of viral nucleic acid sequences comprises viral nucleic acid sequences from NCBI's RefSeq collection, complementary representation of unique regions from Genome Neighbor targets, selected representation of NCBI Influenza Virus Resource sequences, and the entirety of the probe space represented on the Virochip microarray, GEO accession number GPL15905.

BRIEF DESCRIPTION OF THE FIGURES

The application file contains at least one drawing executed in color. Copies of this patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

FIG. 1 depicts the taxonomic distribution of target genomes included in ViroCap. Shown are the viral groups and families included in the ViroCap targeted sequence capture panel. A highlighted subset illustrates underlying genera. To view complete genera for all families, see FIG. 4A. Taxonomic assignments were obtained from the NCBI Taxonomy Viewer

(www.ncbi.nlm.nih.govigenomes/GenomesGroup.cgi?opt=virus&taxid=10239).

FIG. 2A, FIG. 2B, FIG. 2C, FIG. 2D, FIG. 2E, FIG. 2F, FIG. 2G, and FIG. 2H depict targeted sequence capture enrichment. Examples are given showing the impact of targeted sequence capture on breadth and depth of genome coverage for eight representative viral genomes. For illustrative purposes, all of the coverage panels in this figure have been normalized by removing (deduplicating) reads based on identical alignment start-sites. Nucleotide positions along the reference genome are shown on the x-axis. The depth of deduplicated reads is shown on the y-axis. The shaded portion indicates the sequence coverage (breadth and depth) for each virus. Post-capture sequence coverage is represented in the larger panels in blue; precapture sequence coverage is shown in the insets in red. Note that y-axis ranges are different for each panel. At the top of each panel is shown the breadth of coverage (BoC) for the sample. The header of each panel includes breadth of coverage gain (BoC gain), sample id, and reference genome name and NCBI version number. BoC gain is calculated by subtracting the percentage of the length of the reference genome that was covered by sequence reads in precapture MSS from the percentage of the length of the reference genome covered by post-capture sequence reads.

FIG. 3A and FIG. 3B depict targeted sequence capture identifies divergent sequences. (FIG. 3A) The percentage identity of the top high-scoring segment pair (HSP) identified from the BLAST alignment of anellovirus contig sequences to the references used to design ViroCap is plotted on the y-axis. The x-axis represents the percentage of the length of the anellovirus contig covered after targeted sequence capture. (FIG. 3B) This coverage plot represents the sequence coverage of a divergent anellovirus contig sequence. The figure is designed as described in the figure legend for FIG. 2, with the following addition: The post-capture coverage plot is shaded to show regions of nucleotide sequence variation between the anellovirus contig and the most similar reference genome in the ViroCap panel. Dark shading represents areas of identical sequence, and each position with nucleotide mismatch between aligned sequences is shown in the lighter color. All of the HSPs are shown, rather than just the top HSP.

FIG. 4A and FIG. 4B depict the taxonomic distribution of target genomes. (FIG. 4A) Shown are the viral groups, families, and genera included in the ViroCap targeted sequence capture panel. (FIG. 4B) Shown are the viral groups, families and genera included in the samples used in ViroCap validation. Taxonomic assignments for FIG. 4A and FIG. 4B were obtained from the NCBI Taxonomy Viewer

(www.ncbi.nlm.nih.gov/genomes/GenomesGroup.cgi?opt=virus&taxid=10239).

FIG. 5 depicts non-viral read classification based on metagenomic shotgun sequencing before and after viral targeted sequence capture. Classifications of non-viral reads were determined based on nucleotide sequence alignment against bacterial and fungal reference genomes, the human genome, NCBI nt, and capture positive control sequences (positive control probes targeting human genes as included by NimbleGen). The percentages of reads per category are shown on the stacked bar charts and in the data table. For each sample, a small percentage of non-viral reads did not map to any of the reference databases evaluated. Proportions of reads mapping to bacteria/fungi, human, and NCBI nt references was similar pre- and post-capture, indicating the viral capture probes did not consistently or strikingly enrich any other class of organisms expected to be found in these samples. As expected, the positive controls were enriched post-capture in each case.

FIG. 6 depicts human chromosome identities based on metagenomic shotgun sequencing before and after viral targeted sequence capture. The proportions of sequences mapping to each human chromosome and mitochondria are plotted. Viral capture probes did not enrich sequences from human chromosomes. The percentages of human-mapped reads are shown on the stacked bar graphs and in the data table (Table 11).

FIG. 7A, FIG. 7B, FIG. 7C and FIG. 7D depict Genome Neighbor target sequence selection. The general approach for Genome Neighbor target sequence selection is illustrated. While this process is performed on all viral RefSeqs, here we illustrate a small genomic region of a single RefSeq and Genome Neighbor pairing. First, all Genome Neighbor sequences related to a single RefSeq entry are located and associated. In this example, the single Genome Neighbor sequence shown, when compared to RefSeq, has a 100 bp span of alternative sequence (FIG. 7A). The Genome Neighbor sequence is used to generate k-mers of length 100 bp (i.e. capture probe analogs) by means of an exhaustive 1 bp sliding window algorithm, retaining genomic coordinate origin information for each k-mer (FIG. 7A). The resultant set of 100-mers accounts for all potential target sequences that could be used to capture this region. In this example, when comparing Genome Neighbor 100-mers to the corresponding RefSeq genome there is one 100-mer that is completely variant compared to RefSeq, and a set of other 100-mers containing both variant and conserved regions across their lengths due to the nature of the sliding window effect (FIG. 7B). We identify 100-mers that are not represented in the RefSeq genome by sequence clustering (FIG. 7C). Any 100-mers that have >=90% identity to the RefSeq genome are not added to the capture target sequence (Cluster 1, labeled within the figure as “Discarded”). Sequences with <90% identity to RefSeq will form clusters representing variant sequences (Clusters 2-10, labeled within the figure as “Retained”). 100-mers from the variant, non-RefSeq clusters are collected and merged based on genomic coordinates into single, contiguous Genome Neighbor sequence representations used for targeted sequence capture (FIG. 7D).

DETAILED DESCRIPTION OF THE INVENTION

The inventors have designed a panel of probes that specifically hybridize to viral nucleic acid sequences (referred to herein as “the ViroCap panel”) to enhance the sensitivity of metagenomic shotgun sequencing (MSS) for comprehensive detection of known vertebrate viruses, as well as to detect divergent viruses that have nucleotide sequence similarities to known viruses. The inventors have demonstrated that targeted sequence capture using ViroCap dramatically increases the amount of viral sequence obtained from human samples compared with conventional MSS, greatly enhancing the resolution of genomic characterization and increasing the number of viruses detected by >50%. Enhancement was demonstrated for DNA and RNA viruses from multiple diverse families. The increased sensitivity will be valuable in multiple research applications, including descriptions of the human virome, and will also improve the potential for MSS as a diagnostic tool in human and animal health.

The dramatic enrichment of viral nucleic acids present within the targeted sequence capture libraries offers important advantages. First, as the inventors demonstrate, MSS with ViroCap can be used to generate complete or nearly complete genome sequences directly from clinical samples, including those with very low proportions of viral nucleic acid, without culturing the viruses. Availability of extensive sequence data provides the opportunity to distinguish among closely related virus subtypes or even among viral strains, which might not be distinguished by other types of assays. Second, the use of ViroCap can reduce the depth of sequencing needed to detect viruses in samples. Because targeted sequence capture results in a large increase in the percentage of sequencing reads that are viral, ViroCap achieves better viral coverage while requiring the generation of fewer total sequence reads. This increased efficiency has the potential to lower sequencing costs.

I. Methods

The present disclosure provides a method to detect one or more viruses in a sample. The sample may be a sample from a subject, the environment, a laboratory, or any sample in which nucleic acid is present. When the sample is from a subject, the sample may be from a nasopharyngeal swab stool, sputum, urine, plasma, peripheral blood, serum, bone marrow, tissue, and other bodily fluids. In a specific embodiment, the sample is selected from the group consisting of nasopharyngeal swab, stool and plasma. The tissue sample may be a tissue biopsy. The biopsied tissue may be fixed, embedded in paraffin or plastic, and sectioned, or the biopsied tissue may be frozen and cryosectioned. Alternatively, the biopsied tissue may be processed into individual cells or an explant, or processed into a homogenate, a cell extract, a membranous fraction, or a protein extract.

The sample may be used “as is”, processed for cell lysis or disruption of viral particles, or the nucleic acid may be purified from the sample prior to sample preparation. Methods of isolating nucleic acid from a sample are known in the art. In certain embodiments, the isolated nucleic acid is reverse transcribed an amplified after isolation. This allows detection of both RNA and DNA viruses. Specifically, RNA in the total nucleic acid may be reverse transcribed with reverse transcriptase. Random nonomers may then be tagged with a conserved sequence to be used for subsequent amplification. Second strand synthesis may then be carried out using DNA polymerase to generate cDNA for the RNA viruses.

The DNA/cDNA mixture may then be amplified using DNA polymerase. In general, amplification is carried out using polymerase chain reaction (PCR). A PCR reaction may comprise nucleic acid, primers, polymerase, water, buffer, and deoxynucleotide triphosphates (dNTPs). PCR may be performed according to standard methods in the art. By way of non-limiting example, the PCR reaction may comprise denaturation, followed by about 5-10 cycles of denaturation, annealing and extension, followed by a final extension. In an exemplary embodiment, the PCR reaction comprises denaturation at about 98° C. for about 30 seconds, followed by about 5 to about 10 cycles of (about 98° C. for about 10 seconds, about 62-72° C. for about 30 seconds, about 72° C. for about 30 seconds), followed by a final extension at about 72° C. for about 5 minutes. Optionally, the amplified nucleic acid is then purified, for example, via column purification. The nucleic acid in the sample may then be sheared via methods known in the art to generate fragments. The fragments may be about 100 to about 2000 bp. For example, the fragments may be about 200 to about 1500 bp, about 400 to about 1000 bp, about 400 to about 800 bp, or about 500 bp.

If a sample is from a subject, the subject may be a rodent, a human, a livestock animal, a companion animal, a zoological animal, or an invertebrate vector. In one embodiment, the subject may be a rodent, e.g. a mouse, a rat, a guinea pig, etc. In another embodiment, the subject may be a livestock animal. Non-limiting examples of suitable livestock animals may include pigs, cows, horses, goats, sheep, llamas and alpacas. In still another embodiment, the subject may be a companion animal. Non-limiting examples of companion animals may include pets such as dogs, cats, rabbits, and birds. In yet another embodiment, the subject may be a zoological animal. As used herein, a “zoological animal” refers to an animal that may be found in a zoo. Such animals may include non-human primates, large cats, wolves, and bears. Non-limiting examples of suitable invertebrate vectors include mosquitoes, ticks, flies, and lice. In a preferred embodiment, the subject is a human.

A method of the disclosure comprises, in part, contacting a sample with a panel comprising probes capable of specifically hybridizing to greater than 10,000 viral nucleic acid sequences. As used herein, a “probe” is a nucleic acid probe, such as an oligonucleotide of at least 15, 30, 50, 100, 250, 500, 750 or more nucleotides in length, that specifically hybridizes under stringent conditions to a viral nucleic acid. For example, high stringency conditions, such as high hybridization temperature and low salt in hybridization buffers, permit only hybridization between nucleic acid sequences that are highly similar. In a specific embodiment, the probes may be about 50 to about 105 base pairs (bp). In another specific embodiment, the probes may be about 100 bp.

The probes for inclusion in the panel are designed based on a cohort of viral nucleic acid sequences. The cohort of viral nucleic acid sequences may be designed as set forth in the Examples. Specifically, the cohort of viral nucleic acid sequences comprises viral nucleic acid sequences from NCBI's RefSeq collection, complementary representation of unique regions from Genome Neighbor targets, selected representation of NCBI Influenza Virus Resource sequences, and the entirety of the probe space represented on the Virochip microarray (Yu et al. 2012), GEO accession number GPL15905. The cohort of viral nucleic acid sequences comprises viral nucleic acid sequences from all DNA and RNA viruses with sequenced genomes from vertebrate hosts, excluding human endogenous retroviruses and bacteriophages. The cohort of viral nucleic acid sequences comprises more than 150,000, more than 160,000, more than 170,000, or more than 180,000 viral nucleic acid sequences. Specifically, the cohort of viral nucleic acid sequences comprises 185,835 viral nucleic acid sequences. The cohort of viral nucleic acid sequences comprises greater than 150 Mb, greater than 160 Mb, greater than 170 Mb, greater than 180 Mb, or greater than 190 Mb of viral nucleic acid sequences. Specifically, the cohort of viral nucleic acid sequences comprises 198.9 Mb of viral nucleic acid sequences. Even more specifically, the cohort of viral nucleic acid sequences comprises about 27 Mb of viral nucleic acid sequences from RefSeq, about 153 Mb of viral nucleic acid sequences from Genome Neighbor targets, about 16 Mb from Influenza Virus Resource sequences, and about 3 Mb of viral nucleic acid sequences from Virochip microarray. The cohort of viral nucleic acid sequences is used to design a panel of probes that specifically hybridize to the viral nucleic acid sequences of the cohort of viral nucleic acid sequences.

A panel of the disclosure comprises greater than 1×10⁴ probes capable of specifically hybridizing to the viral nucleic acid sequences of the cohort of viral nucleic acid sequences. For example, a panel of the disclosure comprises greater than 1×10⁴ probes, greater than 2×10⁴ probes, greater than 3×10⁴ probes, greater than 4×10⁴ probes, greater than 5×10⁴ probes, greater than 6×10⁴ probes, greater than 7×10⁴ probes, greater than 8×10⁴ probes, greater than 9×10⁴ probes, greater than 1×10⁵ probes, greater than 2×10⁵ probes, greater than 3×10⁵ probes, greater than 4×10⁵ probes, greater than 5×10⁵ probes, greater than 6×10⁵ probes, greater than 7×10⁵ probes, greater than 8×10⁵ probes, greater than 9×10⁵ probes, greater than 1×10⁶ probes, greater than 2×10⁶ probes, greater than 3×10⁶ probes, greater than 4×10⁶ probes, greater than 5×10⁶ probes, greater than 6×10⁶ probes, greater than 7×10⁶ probes, greater than 8×10⁶ probes, greater than 9×10⁶ probes, or greater than 1×10⁷ probes capable of specifically hybridizing to the viral nucleic acid sequences of the cohort of viral nucleic acid sequences. In a specific embodiment, a panel of the disclosure comprises about 2×10⁶ probes capable of specifically hybridizing to the viral nucleic acid sequences of the cohort of viral nucleic acid sequences.

A panel of the disclosure comprises probes capable of specifically hybridizing to greater than 10,000 viral nucleic acid sequences. For example, a panel of the disclosure comprises probes capable of specifically hybridizing to greater than 10,000, greater than 15,000, greater than 20,000, greater than 25,000, greater than 30,000, greater than 35,000, greater than 40,000, greater than 45,000, greater than 50,000, greater than 55,000, greater than 60,000, greater than 65,000, greater than 70,000, greater than 75,000, greater than 80,000, greater than 85,000, greater than 90,000, greater than 95,000, greater than 100,000, greater than 110,000, greater than 120,000, greater than 130,000, greater than 140,000, greater than 150,000, greater than 160,000, greater than 170,000, greater than 180,000, greater than 190,000, or greater than 200,000 viral nucleic acid sequences. In an exemplary embodiment, a panel of the disclosure comprises probes capable of specifically hybridizing to 185,835 viral nucleic acid sequences. For a listing of all the sequences utilized in the ViroCap panel of the disclosure, see Wylie et al., Enhanced virome sequencing using targeted sequence capture. Genome Res 2015; 24(12): 1910-20, the disclosure of which is hereby incorporated by reference in its entirety, including all supplemental information and zip files associated with the publication.

Additionally, a panel of the disclosure comprises probes capable of specifically hybridizing to greater than 50 Mb of viral nucleic acid sequences. For example, a panel of the disclosure comprises probes capable of specifically hybridizing to greater than 50 Mb, greater than 60 Mb, greater than 70 Mb, greater than 80 Mb, greater than 90 Mb, greater than 100 Mb, greater than 110 Mb, greater than 120 Mb, greater than 130 Mb, greater than 140 Mb, greater than 150 Mb, greater than 160 Mb, greater than 170 Mb, greater than 180 Mb, greater than 190 Mb, or greater than 200 Mb of viral nucleic acid sequences. In an exemplary embodiment, a panel of the disclosure comprises probes capable of specifically hybridizing to 198.9 Mb of viral nucleic acid sequences.

Further, a panel of the disclosure comprises probes capable of specifically hybridizing to viral nucleic acid sequences from all DNA and RNA viruses with sequenced genomes from vertebrate hosts, excluding human endogenous retroviruses and bacteriophages. In certain embodiments, a panel of the disclosure comprises probes capable of specifically hybridizing to viral nucleic acid sequences from NCBI's RefSeq collection, complementary representation of unique regions from NCBI Genome Neighbor targets, selected representation of NCBI Influenza Virus Resource sequences, and the entirety of the probe space represented on the Virochip microarray (Yu et al. 2012), GEO accession number GPL15905. The viral nucleic acid sequences may be consolidated via methods described in the Examples. In certain embodiments, a panel of the disclosure comprises probes capable of specifically hybridizing to about 27 Mb of viral nucleic acid sequences from RefSeq, about 153 Mb of viral nucleic acid sequences from Genome Neighbor targets, about 16 Mb from Influenza Virus Resource sequences, and about 3 Mb of viral nucleic acid sequences from Virochip microarray. Importantly, the panel of probes described herein may be continually updated via the methods described herein as new sequences become available.

More specifically, a panel of the disclosure comprises probes capable of specifically hybridizing to viral nucleic acid sequences from 34 viral families comprising 190 annotated viral genera and 337 species. Non-limiting examples of viral families with which the probes are capable of specifically hybridizing to include Adenoviridae, Alloherpesviridae, Asfarviridae, Herpesviridae, Iridoviridae, Malacoherpesviridae, Papillomaviridae, Polyomaviridae, Poxviridae, Birnaviridae, Picobirnaviridae, Reoviridae, Retroviridae, Hepadnaviridae, Parvoviridae, Anelloviridae, Circoviridae, Coronaviridae, Bunyaviridae, Flaviviridae, Orthomyxoviridae, Caliciviridae, Togaviridae, Arenaviridae, Arteriviridae, Astroviridae, Bornaviridae, Filoviridae, Hepeviridae, Paramyxoviridae, Picornaviridae, and Rhabdoviridae. In an exemplary embodiment, a panel of the disclosure comprises probes capable of specifically hybridizing to viral nucleic acid sequences from the viruses depicted in FIG. 4A. In an exemplary embodiment, a panel of the disclosure comprises probes capable of specifically hybridizing to viral nucleic acid sequences from the viruses listed in Table 10.

Hybridization of the probes to the nucleic acid may be done via methods standard in the art. For example, the nucleic acid may first be denatured such that it is single stranded and then the panel of probes and nucleic acid may be incubated at elevated temperature for about 1 to about 72 hours. More specifically, the nucleic acid may be denatured at >95° C. for about 20 minutes and then the panel of probes and nucleic acid may be incubated at about 47° C. for about 64 hours to about 72 hours.

Prior to, during or after hybridization an index sequence and adapter may be attached to the nucleic acid fragments. As used herein, an “adapter” is a sequence that permits universal amplification. A key feature of the adapter is to enable the unique amplification of the hybridized nucleic acid only without the need to remove existing template nucleic acid or purify the hybridized nucleic acid. This feature enables an “add only” reaction with fewer steps and ease of automation. The adapter is attached to the 5′ and 3′ end of the hybridized nucleic acid. The adapter may be Y-shaped, U-shaped, hairpin-shaped, or a combination thereof. In a specific embodiment, the adaptor is Y-shaped. In another specific embodiment, the adapter may be an Illumina adapter for Illumina sequencing. An index sequence may also be attached to each nucleic acid fragment. The addition of an index sequence allows pooling of multiple samples into a single sequencing run. This greatly increases experimental scalability, while maintaining extremely low error rates and conserving read length. The index sequence may be about 5 to about 10 nucleotides. Accordingly, the index sequence may be 5, 6, 7, 8, 9 or 10 or more nucleotides. In an embodiment, the index sequence is about 6 nucleotides.

A method of the disclosure further comprises, in part, isolating the probes that specifically hybridize to viral nucleic acid sequences within the sample. Methods of isolating probes are known in the art. In a specific embodiment, bead purification may be used to isolate the probes that specifically hybridize to viral nucleic acid sequences within the sample. For example, Streptavidin beads may be used. The Streptavidin beads may be incubated with the hybridized sample at about 47° C. for about 45 minutes. The sample may then be washed to remove unbound beads.

The isolated viral nucleic acid sequences may then be amplified. In general, amplification is carried out using polymerase chain reaction (PCR). A PCR reaction may comprise isolated viral nucleic acid, primers, polymerase, water, buffer, and deoxynucleotide triphosphates (dNTPs). PCR may be performed according to standard methods in the art. By way of non-limiting example, the PCR reaction may comprise denaturation, followed by about 10-20 cycles of denaturation, annealing and extension, followed by a final extension. In an exemplary embodiment, the PCR reaction comprises denaturation at about 98° C. for about 30 seconds, followed by about 10 to about 20 cycles of (about 98° C. for about 10 seconds, about 60-72° C. for about 30 seconds, about 72° C. for about 30 seconds), followed by a final extension at about 72° C. for about 5 minutes. Optionally, the amplified viral nucleic acid is then purified, for example, via column purification.

A method of the disclosure further comprises, in part, sequencing the isolated viral nucleic acid sequences. Sequencing may be performed according to standard methods in the art. Sequencing is preferably performed on a massively parallel sequencing platform, many of which are commercially available including, but not limited to Illumina, Roche/454, Ion Torrent, Oxford Nanopore Technologies and PacBio. In an exemplary embodiment, Illumina sequencing is used.

After sequencing of the viral nucleic acid, the sequences are compared with a database comprising reference viral nucleic acid sequences to determine the identity of the viral nucleic acid in the sample. Comparison of sequences generally involves aligning the experimentally determined sequence with a reference sequence. Methods of aligning sequences are known in the art. In a specific embodiment, the alignment algorithm utilized may be BWA-MEM. BWA-MEM is an alignment algorithm for aligning sequence reads or long query sequences against a large reference genome. It automatically chooses between local and end-to-end alignments, supports paired-end reads and performs chimeric alignment. The algorithm is robust to sequencing errors and applicable to a wide range of sequence lengths from 70 bp to a few megabases. For mapping 100 bp sequences, BWA-MEM shows better performance than several state-of-art read aligners to date. The sequence alignments may then be evaluated to determine the identity of the viral nucleic acid in the sample. Methods of evaluating sequence alignments are known in the art. In a specific embodiment, SAMtools is utilized to evaluate the sequence alignments. SAMtools is a set of utilities for interacting with and post-processing short DNA sequence read alignments in the SAM (=Sequence Alignment/Map), BAM (=Binary Alignment/Map) and CRAM formats. Both simple and advanced tools are provided, supporting complex tasks like variant calling and alignment viewing as well as sorting, indexing, data extraction and format conversion.

A method of detecting one or more viruses as described herein increases the number of viruses detected relative to MSS alone. For example, the method of detecting viruses described herein increases the number of viruses detected by greater than 40% relative to MSS alone. Accordingly, the method of detecting viruses described herein increases the number of viruses detected by greater than 40%, greater than 45%, greater than 50%, greater than 55%, greater than 60%, greater than 65%, greater than 70%, greater than 75%, greater than 80%, greater than 85%, greater than 90%, or greater than 95% relative to MSS alone. In a specific embodiment, the method of detecting viruses described herein increases the number of viruses detected by greater than 50% relative to MSS alone.

A method of detecting one or more viruses as described herein increases the breadth of coverage of viral genomes relative to MSS alone. For example, the method of detecting viruses described herein results in a breadth of coverage of greater than 40%. Accordingly, the method of detecting viruses described herein results in a breadth of coverage of greater than 40%, greater than 45%, greater than 50%, greater than 55%, greater than 60%, greater than 65%, greater than 70%, greater than 75%, greater than 80%, greater than 85%, greater than 90%, or greater than 95%. In a specific embodiment, the method of detecting viruses described herein results in a breadth of coverage of greater than 80%. In another specific embodiment, the method of detecting viruses described herein results in a breadth of coverage of greater than 90%.

In certain embodiments, if the sample is a biological sample obtained from a subject, the subject is treated based on the virus detected. Accordingly, a method of the disclosure may be used to diagnose, treat or prevent a disease in a subject. Identification of a virus in a subject could facilitate the diagnosis of a disease, enable the proper methodology, such as a therapeutic, to treat the disease, or prevent the onset of disease by administration of prophylactic therapies. Additionally, identification of anti-viral drug resistant strain could facilitate better treatment strategies.

Importantly, using the methods described herein, a panel of probes could comprise probes that specifically hybridize to bacteria and associated plasmids, fungi, protists, and other microbes. For bacteria, the probes may specifically hybridize to virulence genes such as toxin genes or antibiotic resistance genes. Using the methods described herein, specifically those detailed in the Examples, one of ordinary skill in the art would be able to design a panel of probes to detect a variety of human pathogens. Accordingly, the panel of probes of the disclosure may comprise a comprehensive set of probes to detect a variety of human pathogens. As such, a method of the disclosure may further comprise a method of detecting a pathogen in a sample. As described above, the sample may be environmental or a biological sample obtained from a subject. Additionally, a method of the disclosure may further comprise a method of detecting an infection in a subject. The term “infection” as used herein includes the presence of pathogens in or on a subject, which, if its growth were inhibited, would result in a benefit to the subject. As such, the term “infection” in addition to referring to the presence of pathogens also refers to normal flora which are not desirable. The term “pathogen” as used herein refers to an infectious agent that can produce disease. Non-limiting examples of an infectious agent include virus, bacterium, prion, fungus, viroid, or parasite that cause disease in a subject.

II. Kit

In another aspect, the disclosure provides a kit comprising a panel of the disclosure as described in Section I. More specifically, a kit comprises a panel of probes that specifically hybridize to viral nucleic acid sequences as described in Section I. The kit may also comprise detection agents that can detect hybridization of the probes to the viral nucleic acid sequences of the disclosure, and instructions for use. A person skilled in the art will appreciate that a number of detection agents can be used to detect hybridization of the probes to viral nucleic acid sequences. For example, the detection agent can be a label. The label is preferably capable of producing, either directly or indirectly, a detectable signal. For example, the label may be radio-opaque or a radioisotope, such as ³H, ¹⁴C; ³²P, ³⁵S; ¹²³I; ¹²⁵I; ¹³¹I; a fluorescent (fluorophore) or chemiluminescent (chromophore) compound, such as fluorescein isothiocyanate, rhodamine or luciferin; an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase; an imaging agent; or a metal ion.

The kit can also include a control or reference standard and/or instructions for use thereof. In addition, the kit can include ancillary agents such as vessels for storing or transporting the detection agents and/or buffers or stabilizers.

In certain embodiments, the kit is a nucleic acid array. Such an array may be used to detect viral nucleic acid sequences in a biological sample. An array may be comprised of a substrate having disposed thereon probes of the disclosure capable of hybridizing to the viral nucleic acid sequences of the disclosure.

Several substrates suitable for the construction of arrays are known in the art. The substrate may be a material that may be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid and is amenable to at least one detection method. Alternatively, the substrate may be a material that may be modified for the bulk attachment or association of the nucleic acid and is amenable to at least one detection method. Non-limiting examples of substrate materials include glass, modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, TeflonJ, etc.), nylon or nitrocellulose, polysaccharides, nylon, resins, silica or silica-based materials including silicon and modified silicon, carbon, metals, inorganic glasses and plastics. In an embodiment, the substrates may allow optical detection without appreciably fluorescing.

A substrate may be planar, a substrate may be a well, i.e. a 1534-, 384-, or 96-well plate, or alternatively, a substrate may be a bead. Additionally, the substrate may be the inner surface of a tube for flow-through sample analysis to minimize sample volume. Similarly, the substrate may be flexible, such as a flexible foam, including closed cell foams made of particular plastics. Other suitable substrates are known in the art.

The nucleic acid or biomolecules may be attached to the substrate in a wide variety of ways, as will be appreciated by those in the art. The nucleic acid may either be synthesized first, with subsequent attachment to the substrate, or may be directly synthesized on the substrate. The substrate and the nucleic acid may both be derivatized with chemical functional groups for subsequent attachment of the two. For example, the substrate may be derivatized with a chemical functional group including, but not limited to, amino groups, carboxyl groups, oxo groups or thiol groups. Using these functional groups, the nucleic acid may be attached using functional groups on the biomolecule either directly or indirectly using linkers.

The nucleic acid may also be attached to the substrate non-covalently. For example, a biotinylated nucleic acid can be prepared, which may bind to surfaces covalently coated with streptavidin, resulting in attachment. Alternatively, a nucleic acid or nucleic acids may be synthesized on the surface using techniques such as photopolymerization and photolithography. Additional methods of attaching biomolecules to arrays and methods of synthesizing biomolecules on substrates are well known in the art, i.e. VLSIPS technology from Affymetrix (e.g., see U.S. Pat. No. 6,566,495, and Rockett and Dix, Xenobiotica 30(2):155-177, each of which is hereby incorporated by reference in its entirety).

In one embodiment, the nucleic acid or nucleic acids attached to the substrate are located at a spatially defined address of the array. Arrays may comprise from about 1 to about several hundred thousand addresses. A nucleic acid may be represented more than once on a given array. In other words, more than one address of an array may be comprised of the same nucleic acid. In some embodiments, two, three, or more than three addresses of the array may be comprised of the same nucleic acid. In certain embodiments, the array may comprise control nucleic acids and/or control addresses. The controls may be internal controls, positive controls, negative controls, or background controls.

Furthermore, the nucleic acids used for the array may be labeled. One skilled in the art understands that the type of label selected depends in part on how the array is being used. Suitable labels may include fluorescent labels, chromagraphic labels, chemi-luminescent labels, FRET labels, etc. Such labels are well known in the art.

EXAMPLES

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

Introduction to the Examples

High-throughput, massively parallel nucleotide sequence analysis has made in-depth studies of the human microbiome feasible. Thus far, most microbiome studies have focused on bacteria, although some include fungi. Viruses are particularly understudied, in part due to the challenges of assessing their presence in clinical samples. Viruses as a group have highly variable genomes, with no gene shared among all viruses that can be surveyed by an amplicon-based sequencing strategy. Therefore, studies of viruses based on nucleotide sequencing require a metagenomic approach. Metagenomic shotgun sequencing (MSS) is a relatively unbiased, culture-independent method in which nucleic acid extracted from a sample is sequenced. Sequence reads are classified based on similarity to reference genomes. This approach allows comprehensive study of the viral component of the microbiome (the virome) and has led to the discovery of novel viruses and the characterization of viruses present in healthy and sick people. When adequate numbers of sequence reads are generated, viruses can be characterized with regard to taxonomy and the presence of genes associated with virulence and resistance to antiviral drugs.

A limitation of MSS as employed to date for virus detection is that the amount and proportion of viral nucleic acid in samples from humans may be very low, and in these cases, few viral sequences are generated. In our experience using MSS, we have detected fewer than 10 viral sequences per 25 million sequence reads generated for a virus that was detected in a sample by a molecular assay. In other instances, we have failed to detect viruses known to be present based on molecular assays. These difficulties may reflect the small genome size of some viruses and/or low levels of virus in the sample. This can be a particular problem for studies of the virome of healthy, asymptomatic individuals, in whom virus levels may be low. In efforts to increase the sequence yield, purification or enrichment procedures have been employed, including low-speed centrifugation and/or filtration to remove bacterial and host cells, sample treatment with nucleases to digest nucleic acid not protected within virions, or concentration of viral particles by high-speed gradient centrifugation (for review, see Duhaime and Sullivan 2012). Each of these procedures may bias against detection of some viruses (Breitbart and Rohwer 2005; Young et al. 2014).

An alternative method for enrichment of viral sequences in a metagenomic sample prior to sequencing is targeted sequence capture. Our aim was to develop a comprehensive viral targeted sequence capture panel that could be used to (1) assess all viruses known to infect vertebrate cells and (2) detect divergent viruses. To this end, we created ViroCap, a targeted sequence capture panel that enhances the detection of a comprehensive set of viruses with vertebrate hosts. Here we describe the first application of ViroCap to enrich a broad range of viruses from human clinical samples.

Example 1 Analysis of Clinical and Research Samples with ViroCap

ViroCap includes targets from 34 viral families, comprising 190 annotated viral genera and 337 species (FIG. 1). Included viruses represent all DNA and RNA viruses with sequenced genomes from vertebrate hosts, except human endogenous retroviruses, which were excluded due to their prevalence within the human genome. Nearly 1 billion bp of viral genome sequences were condensed into <200 million bp of targets (Table 3) using k-mer and clustering analyses to define a unique set of reference sequences, as described in the Methods.

We evaluated the effectiveness of detecting DNA and RNA viruses in MSS data compared with ViroCap targeted sequence capture data in two sets of human samples. In experiment 1, the sample set consisted of clinical samples that had been found to be positive by molecular tests in the Diagnostic Virology Laboratory at St. Louis Children's Hospital. Nucleic acid extracts available in the Virology Laboratory were pooled, and a sequencing library was prepared from this pooled nucleic acid (see Methods). In experiment 2, eight patient samples from a research study of young children with fever (Colvin et al. 2012; Wylie et al. 2012) were selected for use in the present study because each had been found to be positive for one or more viruses when tested by batteries of PCR assays used in that study. Individual sequencing libraries were prepared from each of the eight samples as described in the Methods and pooled for sequencing. Experiments 1 and 2 were analyzed in separate sequencing runs. In each experiment, sequencing libraries were divided, and the same library was sequenced without targeted sequence capture (precapture) and following targeted sequence capture using ViroCap (post-capture).

In experiment 1, we detected 10 viruses in the precapture MSS data (Table 1). After targeted sequence capture using the same sequencing library, we detected the same 10 viruses plus four additional viruses. Targeted sequence capture resulted in dramatic improvements in all sequence coverage metrics (Table 1; Table 4), including number and percentage of viral reads, breadth and depth of coverage, and coverage gaps. In experiment 1, the median increase in percentage of viral reads was 674 (range, >13-9335), and the median breadth of coverage increased from 2.1% (range, 0%-89.8%) to 83.2% (range, 0.8%-100%). Illustrative examples are shown in FIG. 2A, FIG. 2B, FIG. 2C, FIG. 2D.

In experiment 2, 11 viruses were detected in the precapture MSS data (Table 2). After targeted sequence capture with ViroCap using the same sequencing libraries, we detected those 11 viruses plus seven additional viruses. Thus, in the two experiments together, the number of viruses detected went from 21 to 32, a 52% increase. All of the viruses detected in both experiments were confirmed by PCR assays except for a torque teno virus in the clinical pool, which was not evaluated by PCR (Table 1, Table 8, Table 9). Viruses detected encompassed 19 genera from 10 families (FIG. 4A, FIG. 4B). In experiment 2, we again found that targeted sequence capture resulted in dramatic improvements in sequencing parameters. In experiment 2, the median fold increase in percentage of viral reads was 296 (range, >56-2722), and the median breadth of coverage increased from 2.0% (range, 0%-99.9%) to 75.6% (range, 13.5%-100%). Illustrative examples are shown in FIG. 2E, FIG. 2F, FIG. 2G, FIG. 2H.

By use of targeted sequence capture, >80% breadth of coverage of the viral genomes was obtained for 16 of 32 viruses, including diverse DNA and RNA genomes of sizes ranging from 5-161 kb (Table 1, Table 2, Table 4, Table 5). Greater than 90% breadth of coverage was obtained for 12 of 32 viruses, and eight viruses had 100% coverage. Precapture, the median gap size in genome coverage was 1704 bp (range 4-152,261 bp), and post-capture, the median gap size was 82 bp (range 0-13,734 bp) (Table 4, Table 5). High genome representation was obtained for multiple viruses in the same capture reaction, as experiments 1 and 2 were each single, independent capture reactions encompassing multiple samples (see Methods).

Example 2 Targeted Sequence Capture Identifies Divergent Viral Sequences

To determine whether or not divergent sequences could be identified using targeted sequence capture, we tested ViroCap on samples containing anelloviruses, a highly divergent group of ssDNA viruses that have a common genome structure but may have up to 30%-50% nucleotide sequence diversity among separate species (Ninomiya et al. 2007; de Villiers et al. 2011). We selected anellovirus-positive samples that we had previously characterized using multistrand displacement amplification followed by high-throughput sequencing. After assembling the precapture sequences to generate contiguous sequences (contigs), we identified anellovirus contigs >1 kb in length. The contigs had varying degrees of similarity to the reference genomes used in the ViroCap panel based on BLAST alignments, ranging from 58%-98% nucleotide sequence identity for the top high-scoring segment pair (HSP) alignment (FIG. 3A; Table 6). All of the contigs assembled using the precapture sequence data were also detected post-capture. The contig with 58% identity to the reference database was missing 13% of its length post-capture (FIG. 3A). The contig with the next lowest percentage identity to the reference database (62%) was fully sequenced (i.e., 100% breadth-of-coverage) (FIG. 3A, FIG. 3B). FIG. 3B illustrates the nucleotide sequence matches/mismatches between the contig and the most similar reference genome in the sequences used for the ViroCap design. These results demonstrate that targeted sequence capture using the ViroCap panel allows us to identify variant virus sequences having as low as 58% nucleotide sequence identity.

Example 3 Specificity of Targeted Sequence Capture

In order to determine whether ViroCap systematically enriched off-target sequences, we compared the filtering and classification statistics of the nonviral sequences in the precapture MSS and targeted sequence capture data (Table 7, FIG. 5, FIG. 6). If our probes were specific, we would not observe any systematic enrichment of specific human chromosomes or bacterial genomes post-capture. However, we anticipated a small amount of variation because the targeted sequence capture library had been through more sample handling in the form of incubations, dilutions, and amplifications. We found that the proportions of the nonviral sequences were strongly correlated (Pearson's correlation value: r=0.9881-0.9996) (Table 7, FIG. 5). A slightly higher percentage (mean, 5.8%; median, 5%; range, 0%-10.7%) of reads aligned to nonviral reference genomes in the post-capture data compared with precapture in all but one of the samples. However, the distribution of sequences among reference genomes did not show a systematic bias. This can be seen in the conserved distribution of sequences among human chromosomes (FIG. 6).

Discussion for the Examples

We designed the ViroCap panel to enhance the sensitivity of MSS for comprehensive detection of known vertebrate viruses, as well as to detect divergent viruses that have nucleotide sequence similarities to known viruses. Here we have demonstrated that targeted sequence capture using ViroCap dramatically increases the amount of viral sequence obtained from human samples compared with conventional MSS, greatly enhancing the resolution of genomic characterization and increasing the number of viruses detected by >50%. Enhancement was demonstrated for DNA and RNA viruses from multiple diverse families. The increased sensitivity will be valuable in multiple research applications, including descriptions of the human virome, and will also improve the potential for MSS as a diagnostic tool in human and animal health.

The dramatic enrichment of viral nucleic acids present within the targeted sequence capture libraries offers important advantages. First, as we demonstrate, MSS with ViroCap can be used to generate complete or nearly complete genome sequences directly from clinical samples, including those with very low proportions of viral nucleic acid, without culturing the viruses. Availability of extensive sequence data provides the opportunity to distinguish among closely related virus subtypes or even among viral strains, which might not be distinguished by other types of assays. In the data set presented here, we demonstrated the ability to type rhinoviruses and distinguish between human herpesvirus 6B and 6A, adenovirus types A and C, and polyomaviruses JC and BK. Notably, influenza A virus was identified precapture but could only be typed as an H3N2 virus post-capture. We used ViroCap to sequence the enterovirus D68 genome directly from clinical samples, and in that work, the extensive sequence data that we obtained allowed us carry out detailed comparative analysis of closely related strains that differed at a limited number of nucleotide positions. Second, the use of ViroCap can reduce the depth of sequencing needed to detect viruses in samples. Because targeted sequence capture results in a large increase in the percentage of sequencing reads that are viral (Table 1, Table 2, Table 4, Table 5, Table 6, FIG. 2), ViroCap achieves better viral coverage while requiring the generation of fewer total sequence reads. This increased efficiency has the potential to lower sequencing costs.

An important feature of ViroCap is the tiling of capture probes across genomes, including highly conserved regions that may allow detection of genomic fragments of divergent viruses that share little overall sequence homology with known viruses. We illustrated such capability using anelloviruses containing divergent nucleotide sequence (FIG. 3). In addition, the inclusion of Genome Neighbor targets enhanced our design not only by expanding beyond the tiled Reference Sequence (RefSeq) viruses but also by adding sensitivity for genomic regions where RefSeq capture probes alone might not have captured divergent strains (see Methods). ViroCap cannot detect viruses that do not share any nucleotide sequence similarity to known viruses; however, we note that because the enrichment of viral nucleic acids occurs after sequence library construction, the uncaptured portion of the library could subsequently be sequenced for additional attempts at pathogen discovery. Furthermore, the ViroCap panel is extensible and will be updated periodically with new viral sequences as they are added to RefSeq and the Genome Neighbors databases. Updates will be publicly available through our GitHub repository (see Data Access).

There were a few genomes (fewer than 10) in the NCBI reference databases that had been cloned into bacterial vectors prior to sequencing, and the deposited viral genome sequences contained bacterial vector sequence. We were not aware of this prior to probe design, so ViroCap includes capture probes that target these sequences. This resulted in enrichment of some sequences (on average 1.1% of total nonviral reads) that were subsequently recognized by our analysis pipeline as bacterial based on nucleotide sequence alignment. In subsequent versions of ViroCap, we will filter out these bacterial vector sequences.

In the experiments reported here, we pooled sequencing libraries prior to targeted sequence capture in order to reduce cost, but we still achieved enhanced detection of multiple viruses of varying abundance. As has been reported for strategies that involve sequencing indexed, pooled libraries (Kircher et al. 2012), we observed some sample cross-contamination. This cross-contamination is recognizable when a high number of viral sequences are detected in the truly positive sample, while few sequences (<0.05% of the viral sequences in the truly positive sample) of the same virus are detected in other samples in the pool. In a clinical setting, each sample would optimally be captured and sequenced independently to reduce the possibility of sample cross-contamination. However, future methodological improvements could allow pooling of clinical specimens.

The success of viral targeted sequence capture is affected by the representation of the virus in the sequencing library. In our sample preparation, total nucleic acid extracted from the sample was reverse transcribed and randomly amplified prior to library construction (Wang et al. 2003), allowing detection of DNA and RNA viral genomes within the same sequencing experiment. The uneven sequence representation observed for some genomes (FIG. 2) is likely due in part to detection of messenger RNA, whose abundance reflects patterns of gene expression, as well as to primer biases during the reverse transcription and amplification steps. Capture hybridization may also induce bias, in that sequences that diverge from target probe sequences may be captured less efficiently than those with exact or nearly exact matches to the probe. Taken together, these data suggest that further improvement in the performance of viral targeted sequence capture may be achievable by improving efficiency of reverse transcription, amplification, and library construction, while continuing to update the ViroCap panel as new, divergent genome sequences become available.

Methods other than genome sequencing have been used for virus characterization and discovery, including Virochip, a microarray-based method for detection/genotyping of viral pathogens (Wang et al. 2002; Chen et al. 2011), and PathoChip, a microarray designed to detect viruses and other microbial pathogens (Baldwin et al. 2014). While designed to detect known viruses by means of microarray probe spotting, this technology has also shown the ability to detect emerging viruses (Wang et al. 2003; Yu et al. 2012). The primary difference between the designs of these microarrays and ViroCap targeted sequence capture is that the latter approach targets complete viral genomes while the microarrays target smaller, discrete genomic regions. The results obtained from each approach also differ significantly. The microarray approach detects the presence of a virus but does not directly provide sequence information. In contrast, MSS enhanced by ViroCap targeted sequence capture provides sequence data, sometimes covering the entire genome.

In conclusion, ViroCap greatly enhances the sensitivity of MSS for nucleotide sequence-based virus detection. To our knowledge, ViroCap represents the first effort to apply a targeted sequence capture approach to the detection of a comprehensive set of viruses. Its research applications are far reaching, allowing a new, higher-resolution view of eukaryotic DNA and RNA viruses in the microbiome. ViroCap should also help realize the potential of MSS as a clinical diagnostic tool that can simultaneously detect viruses and provide immediate characterization, including taxonomic assignment, strain typing, virulence characteristics, and anti-viral drug resistance genotyping. ViroCap could also be modified into a tool for broader pathogen identification, which might include a comprehensive set of human pathogens: genes from viruses, bacteria (e.g., toxin genes, antibiotic resistance genes), fungi, protists, and other microbes.

Methods for the Examples.

Taxonomy selection: At the time, we designed the ViroCap panel, NCBI GenBank had available for download a total of ˜1 Gb of sequence representing 440 viral families, well beyond the 200 Mb of target space supported by the custom SeqCap EZ library format (NimbleGen). Therefore, we developed the following approach for selecting representative targeted sequence capture probes. Because we were interested in studying viral diseases of humans, we excluded bacteriophages and endogenous human retroviruses. We also specifically did not include references from the following NCBI viral reference genome database host categories: algae, archaea, bacteria, diatom, environment, fungi, invertebrates, plants, and protozoa. After filtering, our target list contained reference sequences from the following host categories: human, vertebrates, and “unknown.” This list included viruses that could have both vertebrate and invertebrate hosts, such as vertebrate viruses with insect vectors. Based on these broad viral-host categories, we downloaded all of the associated viral reference sequences in each chosen category from NCBI (accessed Feb. 3, 2014). These sequences comprise the core reference database from which our capture library is designed. Our capture library includes targets from 34 viral families composed of 190 annotated viral genera and 337 species (FIG. 1; Supplemental Tables S6, S7 of Wylie et al., Enhanced virome sequencing using targeted sequence capture. Genome Res 2015; 24(12): 1910-20, the disclosure of which is hereby incorporated by reference in its entirety, including all supplemental information and zip files associated with the publication). Sources of viral sequences include complete representation of the viral genomes from NCBI's RefSeq collection, complementary representation of unique regions from Genome Neighbor targets, selected representation of NCBI Influenza Virus Resource sequences, and the entirety of the probe space represented on the Virochip microarray (Yu et al. 2012), GEO accession number GPL15905. The methods used to consolidate these database sequences follow.

RefSeq: NCBI's RefSeq (www.ncbi.nlm.nih.gov/refseq/) genome collection is a database of taxonomically diverse entries representing comprehensive, well-annotated genome sequences (Pruitt et al. 2014; Tatusova et al. 2014). As RefSeq entries are the most complete sequence representatives in terms of annotation and metadata consistency, we targeted selected viral RefSeqs by tiling of targeted sequence capture probes across the entire length of each RefSeq's genome, with the intention of capturing the entire viral genome. For our capture library, RefSeq nucleotide FASTA sequences were downloaded for desired viral-host categories (human; vertebrates; vertebrates, human; vertebrates, invertebrates; vertebrates, invertebrates, human; invertebrates, vertebrates; unknown) using both the online NCBI taxonomy viewer (www.ncbi.nlm.nih.gov/genomes/GenomesGroup.cgi?opt=virus&taxid=10239), as well as the RefSeq-specific FTP site (ftp.ncbi.nlm.nih.gov/refseq/release/viral). Entries were merged to avoid redundancy. RefSeq targets were pooled with the other sequence candidates (see Design Consolidation). A total of 1456 RefSeq FASTA entries (26.9 Mb) representing 190 viral genera were completely tiled for inclusion in the ViroCap library, accounting for 13.5% of the total capture library's target space.

Genome Neighbors: While RefSeq entries are single, canonical species representations, other complete or partial viral sequences also exist in DDBJ/EMBL/GenBank. In the case of viral sequences, there is extensive redundancy in these databases due to the large number of similar viral strains, isolates, and mutants. Therefore, non-RefSeq (e.g., DDBJ, EMBL, GenBank) nucleotide sequences of complete viral genomes that belong to the same species as a RefSeq sequence are classified as Genome Neighbors for that reference sequence, provided that they match all of the criteria that were used to select complete genomic sequences (Bao et al. 2004). At the time of our ViroCap panel design, Genome Neighbors (sequences downloaded from Entrez Genome link “Other genomes for species”; accessed February 3, 2014) in total represented an additional 56,314 entries and 507.1 Mb of sequence, more than 2.5 times our SeqCap EZ capture target sequence space limit. Therefore, an alternative target selection approach was employed to add diversity to our RefSeq selections by selecting unique, complementary Genome Neighbor sequences.

RefSeq and Genome Neighbor sequence association: We began the process of variant sequence selection by identifying conserved regions in Genome Neighbors already represented by completely tiled RefSeq capture probes. First, we associated our viral RefSeq selections with corresponding Genome Neighbors. This was performed by downloading Genome Neighbor annotation files from NCBI (www.ncbi.nlm.nih.gov/genomes/GenomesGroup.cgi?opt=virus&taxid=10239) and associating the information with our RefSeq annotation files, by means of ad hoc Perl parsing and coupling scripts (for results, see Supplemental Tables S6, S7 of Wylie et al., Enhanced virome sequencing using targeted sequence capture. Genome Res 2015; 24(12): 1910-20, the disclosure of which is hereby incorporated by reference in its entirety, including all supplemental information and zip files associated with the publication). Once associated, the parent RefSeq sequences could be compared with related Genome Neighbor sequences to determine conserved and divergent nucleotide regions. Each viral RefSeq entry was individually reviewed, along with associated Genome Neighbor entries. FASTA sequences were collected for each RefSeq entry and its related Genome Neighbors for subsequent k-mer analysis.

K-mer analysis: Each of the Genome Neighbor sequences was split into 100-bp k-mers by means of an exhaustive 1-bp sliding window algorithm, as depicted in FIG. 7. The resultant output thus included all possible 100-bp sequences based on the combined Genome Neighbor sequence space. As our SeqCap EZ targeted sequence capture probe lengths are 100 bp, the sequences generated by the sliding window algorithm represent the total number of possible probe combinations based on the aggregate of Genome Neighbor sequences. Based on our conservative expectation of hybridization/homology at the capture probe level, we then clustered all of the Genome Neighbor 100-mers back to the parent RefSeq sequence at ≧90% sequence identity using length-sorted FASTA entries and the UCLUST (Edgar 2010) package (version 1.1.579; parameters: -rev -id 0.90). Given that all of our candidate sequences were 100 bp in length and all RefSeq entries are >100 bp, UCLUST always used the longer RefSeq as the first seed (centroid) in which to attempt folding of other sequences. As the parent RefSeq had complete probe tiling in our design, any Genome Neighbor 100-mer with ≧90% identity was considered already represented in our capture library and therefore discarded. Genome Neighbor 100-mers with <90% identity were chosen for inclusion in the capture library. As the sliding window approach produces 100-mers that overlapped one another, we merged overlapping 100-mers based on their Genome Neighbor genomic coordinates into single contiguous spans using BEDTools (Quinlan and Hall 2010) functions.

Genome Neighbor sub-sequences: Resultant subsequences were excised as FASTA entries from corresponding Genome Neighbor references using WU-BLAST's (blast.wustl.edu) xdget application and added to the ViroCap panel. These supplementary entries are easily identifiable in our final target design, as the FASTA headers for the entries list the original parent sequence ID with the excised span indicated in curly braces (e.g., gi|1249624|emb|A28090.1|HPV42 [partial] genomic sequence {SQ 2444-2644}). In this manner, for each RefSeq species, we generated Genome Neighbor subsequences from 100 bp to 21 kb in length to add to our capture panel.

These processing steps reduced the aggregate input Genome Neighbors targeted sequence space from 507.1 Mb to 153.2 Mb (Table 3), and these sequences were pooled with our other targeted capture sequence targets (see Design Consolidation). A total of 130,808 partial Genome Neighbor FASTA entries (153.2 Mb) were added for capture in our ViroCap library, accounting for 77.1% of the total capture library's target space.

Influenza Virus Resource: We obtained reference sequences from NCBI's Influenza Virus Resource database

(www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html), which contains sequence data from the NIAID Influenza Genome Sequencing Project, as well as from GenBank. At the time of our capture panel design, the NCBI Influenza Virus Resource contained 305,524 influenza entries, representing 458.1 Mb of sequence. This is 17 times the size of our viral RefSeq selections and three times the size of our collapsed Genome Neighbor targets. Our selected RefSeq sequences included 29 influenza RefSeq entries (each influenza virus segment is represented as a separate entry), targeted in its entirety. These sequences served as the core of influenza reference genomes against which all other influenza sequences were compared. We directly clustered the long influenza sequences using length-sorted FASTA and the UCLUST package (version 1.1.579; parameters: -rev -id 0.90). In UCLUST, a cluster is defined by one sequence, known as the centroid or representative sequence. To lessen the computational burden and ensure that our core influenza RefSeq genomes were always the longest first seeds (centroids) in UCLUST's clustering process, we artificially concatenated the 29 parent RefSeq sequences into one linear sequence representation and then split this representation into six segments ranging in size from 18-26 kb. UCLUST preferentially seeded with the long RefSeq construct segments when clustering, ensuring that clustering was first attempted within the longer, canonical references. ULCUST was run with a requirement of ≧90% sequence identity to fold into a parent influenza RefSeq entries segment. Therefore, only sequences that (1) had <90% identity to influenza RefSeq entries and (2) were subsequent centroids in non-RefSeq clusters were chosen for inclusion in our capture panel. This process reduced the aggregate input Influenza Resource Database reference sequence from 458.1 Mb to 15.7 Mb (Table 3). Finally, supplementary influenza targets were pooled with the other sequence candidates (see Design Consolidation). A total of 9759 influenza FASTA entries (15.7 Mb) were added for targeted sequence capture in our ViroCap library, accounting for 7.9% of the total capture library's target space.

Virochip microarray: Considering the biologically important short sequence signatures represented on the Virochip panel (Yu et al. 2012), as well as the comparatively small footprint, we subsumed these sequences within our targeted sequence capture panel design. The probe sequences for the microarray are publicly available at NCBI's Gene Expression Omnibus (GEO) repository (Edgar et al. 2002). We downloaded this information for Platform GPL15905 (Viro5AG-60k) as a text file (www.ncbi.nlm.nih.govigeo/query/acc.cgi?acc=GPL15905). This platform included more than 60,000 oligonucleotides of length 60-70 bp, corresponding to 3.1 Mb of probes (Table 3). Virochip targets were pooled with the other sequence candidates (see Design Consolidation). Upon review, 1.3 Mb of the probes were already directly represented by RefSeq, Genome Neighbor, and Influenza Viral Resource sequences during capture library design and synthesis. Therefore, the remaining 25,749 (60-70 bp) Virochip FASTA entries of 1.8-Mb total size were added to ViroCap, accounting for <1% of the total targeted sequence capture panel.

Design consolidation: All of our selected candidate target sequences from RefSeq, Genome Neighbors, Influenza Virus Resource, and the Virochip microarray were combined into a single FASTA sequence file. Human endogenous retroviruses were removed from inclusion by means of a two-part process: (1) Entries were filtered by taxonomic annotation indicating human endogenous retrovirus identity, and (2) the remaining entries were BLAST-aligned to the GRCh37-lite build of the human reference genome to remove sequences with high percentage identity (≧75%) at the 100-bp probe level. Finally, sequences were hard-masked (i.e., bases converted to N′s) in low complexity regions using the DUST (R Tatusov and DJ Lipman, unpubl.) software module. The final ViroCap targeted sequence capture panel consists of 185,835 FASTA sequences totaling 198.9 Mb (see Taxonomy Selection).

NimbleGen sequence capture design: Our consolidated target sequences were submitted to Roche NimbleGen for capture library design and synthesis. As our final ViroCap design required 198.9 Mb, manufacturing was implemented under the custom NimbleGen SeqCap EZ Developer Library format, which has a maximum capture space of 200 Mb of nonhuman sequence. NimbleGen's Sequence Capture design offered up to 2.1 million of 50-105 mer sequence probes. It was at the discretion of NimbleGen, based on proprietary algorithms, to redistribute probes for better capture uniformity, redundancy, and comprehensive target base coverage. NimbleGen provided us with a proposed capture design accompanied by coordinate (GFF, BED) files and associated sequence coverage metrics. The design set contained probe representation generated by first masking all but one exact copy of each 100-mer in our original FASTA file, tiling the unmasked regions, screening the resulting probes against the (hg19) human genome, and finally selecting only those probes that had no matches in the human genome as determined by the SSAHA (Ning et al. 2001) algorithm. NimbleGen provides two metrics for assessing in silico targeted sequence capture design coverage: (1) Target bases covered with 0-bp-offset are determined by counting target bases directly represented in probe sequences, and (2) target bases covered with 100-bp-offset are determined by counting all target bases within 100 bp of a probe. The capture design provided 95.9% 0-bp-offset coverage and 99.6% 100-bp-offset coverage of our initial 198.9-Mb target request. We approved the design for capture library synthesis and received our first 12 SeqCap EZ Library reactions for in-house Illumina sequencing and analysis.

Human subjects approval and sample selection: Samples were collected under protocols approved by the Human Research Protection Office at Washington University School of Medicine (IRB protocol nos. 201106177, 201102561, and 201102045). Samples were selected to represent a broad range of viruses that are commonly encountered in the clinical laboratory and in our research studies. Viruses were identified in samples based on clinical laboratory test results in the Diagnostic Virology Laboratory at St. Louis Children's Hospital or by PCR assays and sequencing results carried out in previous studies (Colvin et al. 2012; McElvania TeKippe et al. 2012; Wylie et al. 2012). Specimens of nasopharyngeal secretions, plasma, and stool were included.

Sequencing: Total nucleic acid was extracted from clinical samples using the EasyMag NucliSENS instrument (bioMerieux). Samples were processed in one of two ways. In experiment 1, nucleic acids from clinical specimens from the Diagnostic Virology Laboratory were combined, and the resulting pooled nucleic acid was used as input for a single sequencing library (constructed as described below). These samples are designated with a sample identification prefix of “P” in the various tables and figures. Alternatively, in experiment 2, individual sequencing libraries were made from each set of eight different specimens prior to combining the libraries for sequencing. These samples are designated with a sample identification prefix of “S” in the various tables.

For sequencing libraries, DNA and RNA viruses were assessed in the same assay as previously described (Wang et al. 2003). Specifically, the RNA in the total nucleic acid was reverse transcribed with reverse transcriptase (Promega) and random nonomers tagged with a conserved sequence (5′-GTTTCCCAGTCACGATA-3′-SEQ ID NO:1) to be used for subsequent amplification (Integrated DNA Technologies), and second strand synthesis was carried out with Sequenase V2.0 DNA polymerase (Affymetrix). DNA and RNA were subsequently amplified with Accuprime Taq (Life Technologies) using the conserved sequence on the ends of the random primers, and the DNA/cDNA mixture was sheared using the Qsonica Q800R instrument (Qsonica) to generate fragments with an average length of 500 bp. Dual-indexed sequencing libraries were constructed using the KAPA low throughput library construction kit (KAPA Biosystems).

For the anellovirus samples, DNA was amplified with the Illustra Genomi Phi V2 DNA amplification kit (GE Healthcare Life Sciences); RNA was not assessed. DNA was sheared, and libraries were constructed from each sample as described above. Sequencing libraries were pooled.

In each case, the libraries were divided, and part was directly sequenced (precapture) and part was subjected to targeted sequence capture with the custom ViroCap probes prior to sequencing (post-capture). Targeted sequence capture was carried out according to the manufacturer's specifications. We carried out 10, 10, and 16 cycles of post-capture linker—mediated PCR for experiments 1 (pooled clinical samples), 2 (individual samples from the research study), and 3 (anellovirus samples), respectively, prior to sequencing. The number of cycles was empirically determined to be the minimum number needed to obtain a 5 nM dilution of library material for qPCR and loading. Libraries were sequenced on the Illumina HiSeq 2000 or HiSeq 2500 instrument, generating 100-bp paired-end reads.

Sequence analysis: Viral sequences were identified based on nucleotide and translated protein sequence alignment against reference genomes. The pipeline is adapted from previously described methods (Wylie et al. 2014), except that nucleotide alignments were carried out using BWA-MEM with default settings (Li and Durbin 2009). Because many similar genomes are included in the reference database, we used the initial alignment statistics for each sample to choose a single reference from each species to calculate and report coverage statistics. References were chosen based on having the highest number of reference bases covered. Sequences were realigned to the selected references with BWA-MEM for calculation of coverage statistics and comparison of samples precapture and post-capture. Sequence alignments were evaluated with SAMtools (Li 2011), and sequence coverage was determined with RefCov (gmt.genome.wustl.edu/packages/refcov/) and visualized with Plot2 (plot2doc.micw.eu). For illustrative purposes, the genome coverage panels in FIG. 2 and FIG. 3 were normalized by removing (deduplicating) reads based on identical alignment start sites using the SAMtools rmdup command. For each alignment start site, only the highest-quality read was retained for forward and reverse alignment orientations. Therefore, for the 100-bp read data shown in each coverage panel, the theoretical maximum depth is 200×.

Anellovirus contigs were assembled from the precapture sequence data using IDBA-UD (Peng et al. 2012). Contigs were aligned against the sequence database used to design the ViroCap panel using BLAST (Altschul et al. 1997) with the following parameters to detect low-similarity sequences: -G 5-E 2-r1-q-1. The percentage identity of the top HSP is reported in Table 5.

REFERENCES FOR THE EXAMPLES

1. Albert T J, Molla M N, Muzny D M, Nazareth L, Wheeler D., Song X, Richmond T A, Middle C M, Rodesch M J, Packard C J, et al. 2007. Direct selection of human genomic lad by microarray hybridization. Nat Methods 4: 903-905.

2. Allander T, Emerson S U, Engle R E, Purcell R H, Bukh J. 2001. A virus discovery method incorporating DNase treatment and its application to the identification of two bovine parvovirus species. Proc Natl Acad Sci 98: 11609-11614.

3. Altschul S F, Madden T L, Schaffer A A, Zhang J, Zhang Z, Miller W, Lipman D J. 19 97. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389-3402.

Arumugam M, Raes J, Pelletier E, LePaslier D, Yamada T, Mende DR, Fernande sGR, Tap J, Bruls T, Batto J -M, et al. 2011. Enterotypes of the human gut microbiome. Nature 473: 174-180.

5. Baldwin D A, Feldman M, Alwine J C, Robertson E S. 2014. Metagenom c assay for identification of microbial pathogens in tumor tissues. MBio 5: e01714-14.

6. Bao Y, Federhen S, Leipe D, Pham V, Resenchuk S, Rozanov M, Tatusov R, Tat usova T. 2004. National center for biotechnology information viral genomes project. J Viral 78: 7291-7298.

7. Breitbart M, Rohwer F. 2005. Method for discovering novel DNA viruses in blood using viral particle selection and shotgun sequencing. Biotechniques 39:729-736.

8. Chen E C, Miller S A, DeRisi J L, Chiu C Y. 2011. Using a pan-viral microarray assay (Virochip) to screen clinical samples for viral pathogens. J Vis Exp 2536.

9. Chiu CY. 2013. Viral pathogen discovery. Curr Opin Microbial 16: 468-478.

10. Cleland E J, Bassioni A, Boase S, Dowd S, Vreugde S, Wormald P -J. 2014. The fungal microbiome in chronic rhinosinusitis: richness, diversity, postoperative changes and patient outcomes. Int Forum Allergy Rhinol 4: 259-265.

11. Colvin J M, Muenzer J T, Jaffe D M, Smason A, Deych E, Shannon W O, Arens M, Buller R S, Lee W M, Weinstock E J S, et al. 2012. Detection of viruses in young children with fever without an apparent source. Pediatrics 130: e1455-e1462.

12. de Villiers E -M, Borkosky S S, Kimmel R, Gunst K, Fei J -W. 2011. The diversity of torque tend viruses: in vitro replication leads to the formation of additional replication-competent subviral molecules. J Viral 85: 7284-7295.

13. DeVlaminck I, Khush K K, Strehl C, Kohli B, Luikart H. Neff N F, Okamoto J, Snyder T M, Cornfield O N, Nicolls M R, et al. 2013. Temporal response of the human virome to immunosuppression and antiviral therapy. Cell 155:1178-1187.

14. Depledge D P, Falser A L, Watson S J, Lai I Y C, Gray E R, Grant P, Kanda R K, Leproust E, Kellam P, Breuer J. 2011. Specific capture and whole-genome sequencing of viruses from clinical samples. PLoS One 6: e27805.

15. Duhaime M B, Sullivan M B. 2012. Ocean viruses: rigorously evaluating the metagenomic sample-to-sequence pipeline. Virology 434: 181-186.

16. Duncavage E J, Magrini V, Becker N, Armstrong J R, Demeter R T, Wylie T, Abel H J, Pfeifer J D. 2011. Hybrid capture and next-generation sequencing identify viral integration sites from formalin-fixed, paraffin-embedded tissue. J Mol Diagn 13:325-333.

17. Edgar R C. 2010. Search and clustering orders of magnitude faster than BLAST. Bioinforrnatics 26: 2460-2461.

18. Edgar R, Domrachev M, Lash A E. 2002. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30:207-210.

19. Findley K, Oh J, Yang J, Conlan S, Deming C, Meyer J A, Schoenfeld D, Nomicos E, Park M; NIH Intramural Sequencing Center Comparative Sequencing Program, et al. 2013. Topographic diversity of fungal and bacterial communities in human skin. Nature 498: 367-370.

20. Gajer P, Brotman R M, Bai G, Sakamoto J, Schutte U M E, Zhong X, Koenig S S K, FuL, Ma Z S, Zhou X, et al. 2012. Temporal dynamics of the human vaginal microbiota, Sci Trans! Med 4: 132ra52.

21. Hodges E, Xuan Z, Balija V, Kramer M, Molla M N, Smith S W, Middle C M, Rodesc h M J, Albert T J, Hannon G J, et al. 2007. Genome-wide in situ exon capture for selective resequencing. Nat Genet 39: 1522-1527.

22. Holtz L R, Cao S, Zhao G, Bauer I K, Denno D M, Klein E J, Antonio M, Stine O C, Snelling T L, Kirkwood C D, et al. 2014. Geographic variation in the eukaryotic virome of human diarrhea. Virology 468-470: 556-564.

23. Human Microbiome Project Consortium. 2012. Structure, function and diversity of the healthy human microbiorne. Nature 486: 207-214.

24. Kircher M, Sawyer S, Meyer M. 2012. Double indexing overcomes inaccuracies in multiplex sequencing on the lumina platform. Nucleic Acids Res 40: e3.

25. Koehler J W, Hall A T, Rolfe P A, Honko A N, Palacios G F, Fair J N, Muyembe J -J, Mulernbekani P, Schoepp R J, Adesokan A, et al. 2014. Development and evaluation of a panel of filovirus sequence capture probes for pathogen detection by next-generation sequencing. PLoS One 9: e107007

26. Li H. 2011. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics 27: 2987-2993.

27. Li H, Durbin R, 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754-1760.

28. Lovett M, Kere J, Hinton L M. 1991. Direct selection: a method for the isolation of cDNAs encoded by large genomic regions. Proc Natl Acad Sci 88: 9628-9632.

29. Lysholm F, Wetterbom A, Lindau C, Darban H, Bjerkner A, Fahlander K, Lindberg A M, Persson B, Allander T, Andersson B. 2012. Characterization of the viral microbiome in patients with severe lower respiratory tract infections, using metagenomic sequencing. PLoS One 7: e30875.

30. McElvaniaTeKippe E, Wylie K M, Deych E, Sodergren E, Weinstock G, Starch G A 2012. Increased prevalence of anellovirus in pediatric patients with fever. PLoS One 7: e50937.

31. Minot S, Sinha R, Chen J, Li H, Keilbaugh S A, Wu G D, Lewis J D, Bushman FD.2 011. The human gut virome: inter-individual variation and dynamic response to diet. Genome Res 21: 1616-1625.

32. Ning Z, Cox A J, Mullikin J C. 2001. SSAHA: a fast search method for arge DNA databases. Genome Res 11: 1725-1729.

33, Ninomiya. M, Takahashi M, Shimosegawa T, Okamoto H. 2007. Analysis of the entire genomes of fifteen torque tend midi virus variants classifiable into a third group of genus Aneilovirus. Arch Viral 152: 1961-1975.

34. Oh J, Byrd A L, Deming C, Conlan S; NISC Comparative Sequencing Program, Kong H H, Segre J A. 2014. Biogeography and individuality shape function in the human skin metagenome. Nature 514: 59-64.

35. Okou D T, Steinberg K M, Middle C, Cutler D J, Albert T J, Zwick M E. 2007. Microar ray-based genomic selection for high-throughput resequencing. Nat Methods 4: 907-909.

36. Paulino L C, Tseng C -H, Strober B E, Blaser M J. 2006. Molecular analysis of fungal microbiota in samples from healthy human skin and psoriatic lesions. J Clin Microbial 44: 2933-2941.

37. Peng Y, Leung H C M, Yiu S M, Chin F Y L. 2012. IDBA-UD: a de novo assembler for single-cell and metagenomic sequencing data with highly uneven depth.Bioinformatics 28: 1420-1428.

38. Pruitt K D, Brown G R, Hiatt S M, ThibaudNissen F, Astashyn A, Ermolaeva O, Farrell C M, Hart J, Landrum M J, McGarvey K M, et al. 2014. RefSeq: an update on mammalian reference sequences. Nucleic Acids Res 42: D756-0763.

39. Quinlan A R, Hall I M. 2010. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26: 841-842.

40. Reyes A, Haynes M, Hanson N, Angly F E, Heath A C, Rohwer F, Gordon J I. 2010. Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature 466: 334-338.

41. Tatusova T, Ciufo S, Fedorov B, O'Neill K, Tolstoy I. 2014. RefSeq microbial genomes database: new representation and annotation strategy. Nucleic Acids Res 42: D553-D559.

42. Turnbaugh P J, Hamady M, Yatsunenko T, Cantarel B L, Duncan A, Ley R E, Sogi nML, Jones W J, Roe B A, Affourtit J P, et al. 2009. A core gut microbiome in obese and lean twins. Nature 457: 480-484.

43. Wang O, Coscoy L, Zylberberg M, Avila P C, Boushey H A, Ganem D, DeRisi J L. 2002. Microarray-based detection and genotyping of viral pathogens. Proc Natl Acad Sci 99: 15687-15692.

44. Wang D, Urisman A, Liu YT, Springer M, Ksiazek T G, Erdman O D, Mardis E R, Hickenbotham M, Magrini V, Eldred J, et al. 2003. Viral discovery and sequence recovery using DNA microarrays. PLoS Biol 1: E2.

45. Willger S D, Grim S L, Dolben E L, Shipunova A, Hampton T H, Morrison H G, Filkin sLM, O'Toole G A, Moulton L A, Ashare A, et al. 2014. Characterization and quantification of the fungal rnicrobiome in serial samples from individuals with cystic fibrosis. Microbiome 2: 40.

46. Wylie K M, Mihindukulasuriya K A, Sodergren E, Weinstock G M, Starch G A. 2012. Sequence analysis of the human virome in febrile and afebrile children. PLoS One7: e27735.

47. Wylie K M, Mihindukulasuriya K A, Zhou Y, Sodergren E, Starch G A, Weinstock G M. 2014. Metagenomic analysis of double-stranded DNA viruses in healthy adults. BMC Biol 12: 71.

48. Wylie K M, Wylie T N, Orvedahl A, Buller R S, Herter B N, Magrini V, Wilson R K, Storch G A. 2015. Genome sequence of enterovirus D68 from St. Louis, Mo., USA. Emerging Infect Dis 21: 184-186.

49. Young J C, Chehoud C, Bittinger K, Bailey A, Diamond J M, Cantu E, Haas A R, Abbas A, Frye L, Christie J D, et al. 2014. Viral metagenomics reveal blooms of anelloviruses in the respiratory tract of lung transplant recipients. Am J Transplant 15: 200-209.

50. Yu G, Greninger A L, Isa P, Phan T G, Martinez M A, Ia Luz Sanchez de M, Contreras J F, Santos-Preciado J I, Parsonnet J, Miller S, et al. 2012. Discovery of a novel polyomav rus in acute diarrheal samples from children. PLoS One 7:e49449.

Lengthy table referenced here US20170218465A1-20170803-T00001 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20170218465A1-20170803-T00002 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20170218465A1-20170803-T00003 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20170218465A1-20170803-T00004 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20170218465A1-20170803-T00005 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20170218465A1-20170803-T00006 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20170218465A1-20170803-T00007 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20170218465A1-20170803-T00008 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20170218465A1-20170803-T00009 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20170218465A1-20170803-T00010 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20170218465A1-20170803-T00011 Please refer to the end of the specification for access instructions.

LENGTHY TABLES The patent application contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20170218465A1). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3). 

What is claimed is:
 1. A method to detect one or more viruses in a sample, the method comprising: a) contacting a sample with a panel comprising probes capable of specifically hybridizing to greater than 10,000 viral nucleic acid sequences; b) isolating the probes that specifically hybridize to viral nucleic acid sequences within the sample; c) sequencing the viral nucleic acid sequences isolated; and d) comparing the sequences from (c) with a database comprising reference viral nucleic acid sequences to determine the identity of the viral nucleic acid in the sample.
 2. The method of claim 1, wherein nucleic acid is isolated prior to step (a).
 3. The method of claim 2, wherein isolated nucleic acid is reverse transcribed and amplified prior to step (a) thereby allowing detection of DNA and RNA viral nucleic acid.
 4. The method of claim 3, wherein the nucleic acid is sheared to generate fragments with an average length of 500 bp.
 5. The method of claim 1, wherein the panel comprises about 2×10⁶ probes capable of specifically hybridizing to the viral nucleic acid sequences.
 6. The method of claim 1, wherein the panel comprises probes capable of specifically hybridizing to greater than 50,000 viral nucleic acid sequences.
 7. The method of claim 1, wherein the probes are about 50 to about 105 bp.
 8. The method of claim 1, wherein the panel comprises probes capable of specifically hybridizing to greater than 50 Mb of viral nucleic acid sequences.
 9. The method of claim 1, wherein the panel comprises probes capable of specifically hybridizing to more than 1 virus listed in FIG. 4A.
 10. The method of claim 1, wherein the sample is a biological sample obtained from a subject.
 11. The method of claim 10, wherein the biological sample is selected from the group consisting of nasopharyngeal swab, stool and plasma.
 12. The method of claim 10, wherein the subject is treated based on the virus detected.
 13. A kit for detecting viral nucleic acid, the kit comprising probes capable of specifically hybridizing to greater than 10,000 viral nucleic acid sequences.
 14. The kit of claim 13, wherein the probes specifically hybridize to a cohort of viral nucleic acid sequences, the cohort of viral nucleic acid sequences comprising viral nucleic acid sequences from NCBI's RefSeq collection, complementary representation of unique regions from Genome Neighbor targets, selected representation of NCBI Influenza Virus Resource sequences, and the entirety of the probe space represented on the Virochip microarray, GEO accession number GPL15905.
 15. The kit of claim 14, wherein the cohort of viral nucleic acid sequences comprises viral nucleic acid sequences from all DNA and RNA viruses with sequenced genomes from vertebrate hosts, excluding human endogenous retroviruses and bacteriophages.
 16. The kit of claim 14, wherein the cohort of viral nucleic acid sequences comprises more than 150,000 viral nucleic acid sequences.
 17. The kit of claim 14, wherein the cohort of viral nucleic acid sequences comprises greater than 150 Mb of viral nucleic acid sequences.
 18. The kit of claim 14, wherein the cohort of viral nucleic acid sequences comprises about 27 Mb of viral nucleic acid sequences from RefSeq, about 153 Mb of viral nucleic acid sequences from Genome Neighbor targets, about 16 Mb from Influenza Virus Resource sequences, and about 3 Mb of viral nucleic acid sequences from Virochip microarray.
 19. The kit of claim 14, wherein the cohort of viral nucleic acid sequences is used to design a panel of probes that specifically hybridize to the viral nucleic acid sequences of the cohort of viral nucleic acid sequences.
 20. The kit of claim 14, wherein the cohort of viral nucleic acid sequences comprises viral nucleic acid sequences from 34 viral families comprising 190 annotated viral genera and 337 species. 